City of Hope’s Post

From the Founder, Ambreén Z Riaz. Emerging advancements in oncology, such as precision medicine and personalized therapies, continue to revolutionize cancer treatment by offering more effective and less invasive options with fewer side effects. With the field of oncology continuously evolving, there is hope for improved outcomes and better quality of life for cancer patients. Innovation and precision are key to faster and better results. Here are some examples of oncology therapies that might alter the adverse outcomes for patients: - Immunotherapy: This approach harnesses the body's immune system to fight cancer. Examples include checkpoint inhibitors like pembrolizumab and nivolumab. - CAR-T Cell Therapy: This involves modifying a patient's own immune cells to better recognize and destroy cancer cells. Examples include Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). - Targeted Therapy: These drugs specifically target cancer cells by interfering with specific molecules involved in tumor growth and progression. Examples include Herceptin (trastuzumab) for HER2-positive breast cancer and Gleevec (imatinib) for chronic myeloid leukemia (CML). - Precision Medicine: This approach involves tailoring treatment plans based on a patient's unique genetic makeup, tumor characteristics, and other factors. - Radiosensitizers and Radioprotectors: These agents enhance the effectiveness of radiation therapy while protecting healthy tissues from radiation damage. Examples include nimorazole and amifostine. - Nanotechnology-Based Therapies: Nanoparticle-based drug delivery systems are being developed to improve the efficacy and reduce the side effects of chemotherapy. Examples include Abraxane (albumin-bound paclitaxel) and Onivyde (liposomal irinotecan). With these advancements, we can expect to see more targeted and effective treatments for cancer patients. #oncology #cancertreatment #precisionmedicine #immunotherapy #CAR-T #targetedtherapy

Emerging advancements in oncology, such as precision medicine and personalized therapies, continue to revolutionize cancer treatment by offering more effective and less invasive options with fewer side effects. With the field of oncology continuously evolving, there is hope for improved outcomes and better quality of life for cancer patients. Innovation and precision are key to faster and better results. Here are some examples of oncology therapies that might alter the adverse outcomes for patients: - Immunotherapy: This approach harnesses the body's immune system to fight cancer. Examples include checkpoint inhibitors like pembrolizumab and nivolumab. - CAR-T Cell Therapy: This involves modifying a patient's own immune cells to better recognize and destroy cancer cells. Examples include Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). - Targeted Therapy: These drugs specifically target cancer cells by interfering with specific molecules involved in tumor growth and progression. Examples include Herceptin (trastuzumab) for HER2-positive breast cancer and Gleevec (imatinib) for chronic myeloid leukemia (CML). - Precision Medicine: This approach involves tailoring treatment plans based on a patient's unique genetic makeup, tumor characteristics, and other factors. - Radiosensitizers and Radioprotectors: These agents enhance the effectiveness of radiation therapy while protecting healthy tissues from radiation damage. Examples include nimorazole and amifostine. - Nanotechnology-Based Therapies: Nanoparticle-based drug delivery systems are being developed to improve the efficacy and reduce the side effects of chemotherapy. Examples include Abraxane (albumin-bound paclitaxel) and Onivyde (liposomal irinotecan). With these advancements, we can expect to see more targeted and effective treatments for cancer patients. #oncology #cancertreatment #precisionmedicine #immunotherapy #CAR-T #targetedtherapy

📃Scientific paper: Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy Abstract: [Image: see text] Cancer immunotherapy has become an established therapeutic paradigm in oncologic therapy, but its therapeutic efficacy remains unsatisfactory in the majority of cancer patients. Accumulating evidence demonstrates that the metabolically hostile tumor microenvironment (TME), characterized by acidity, deprivation of oxygen and nutrients, and accumulation of immunosuppressive metabolites, promotes the dysfunction of tumor-infiltrating immune cells (TIICs) and thereby compromises the effectiveness of immunotherapy. This indicates the potential role of tumor metabolic intervention in the reinvigoration of antitumor immunity. With the merits of multiple drug codelivery, cell and organelle-specific targeting, controlled drug release, and multimodal therapy, tumor metabolism-rewriting nanomedicines have recently emerged as an attractive strategy to strengthen antitumor immune responses. This review summarizes the current progress in the development of multifunctional tumor metabolism-rewriting nanomedicines for evoking antitumor immunity. A special focus is placed on how these nanomedicines reinvigorate innate or adaptive antitumor immunity by regulating glucose metabolism, amino acid metabolism, lipid metabolism, and nucleotide metabolism at the tumor site. Finally, the prospects and challenges in this emerging field are discussed. Continued on ES/IODE ➡️ https://etcse.fr/X87 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

𝐓𝐡𝐞 R𝐢𝐬𝐞 𝐨𝐟 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐃𝐞𝐠𝐫𝐚𝐝𝐞𝐫𝐬 A groundbreaking approach in cancer treatment is emerging, as highlighted in the notable review article by Deborah Chirnomas, Keith R. Hornberger, and Craig M. Crews in Nature Reviews Clinical Oncology. This piece, "Protein degraders enter the clinic — a new approach to cancer therapy," marks a pivotal shift in oncological therapeutics, spotlighting the evolution and clinical entry of heterobifunctional protein degraders. 𝐓𝐡𝐞 𝐏𝐚𝐫𝐚𝐝𝐢𝐠𝐦 𝐒𝐡𝐢𝐟𝐭 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝘍𝘳𝘰𝘮 𝘛𝘳𝘢𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘔𝘦𝘵𝘩𝘰𝘥𝘴 𝘵𝘰 𝘗𝘳𝘰𝘵𝘦𝘪𝘯 𝘋𝘦𝘨𝘳𝘢𝘥𝘦𝘳𝘴 Traditionally, cancer therapy relied heavily on chemotherapy, radiotherapy, and surgery. However, these methods often pose significant limitations due to their non-specific targeting, leading to severe toxicities and long-term adverse effects. The advent of protein degraders, particularly PROteolysis TArgeting Chimera protein degraders, represents a fundamental shift. These innovative agents utilize the body's ubiquitin–proteasome system to selectively target and eliminate proteins involved in disease pathogenesis. 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐓𝐫𝐢𝐚𝐥𝐬 𝘌𝘮𝘦𝘳𝘨𝘪𝘯𝘨 𝘋𝘢𝘵𝘢 𝘢𝘯𝘥 𝘗𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨 𝘖𝘶𝘵𝘤𝘰𝘮𝘦𝘴 By January 2023, 18 heterobifunctional protein degraders were under clinical trials for various cancers, with phase III trials already underway. Early clinical data are promising, indicating the potential of these agents as effective cancer therapies. Their unique mechanism of action allows for sub-stoichiometric drug concentrations, potentially overcoming the limitations of traditional small-molecule inhibitors. 𝐓𝐚𝐫𝐠𝐞𝐭 𝐒𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘤 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘙𝘰𝘢𝘥 𝘈𝘩𝘦𝘢𝘥 The selection of therapeutic targets for protein degraders is a critical step, focusing on previously 'undruggable' proteins and addressing issues like resistance mutations and gene amplification. The framework proposed for target selection involves six key areas, leveraging the unique pharmacology of protein degraders. 𝐂𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝘕𝘦𝘹𝘵-𝘎𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘊𝘢𝘯𝘤𝘦𝘳 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘰𝘯 𝘵𝘩𝘦 𝘏𝘰𝘳𝘪𝘻𝘰𝘯 The evolution of protein degraders from concept to clinical trials is a testament to the relentless pursuit of more effective cancer treatments. While more data are needed, the initial results are a beacon of hope for patients and a promising direction for future cancer therapy innovations. #CancerTherapy #ProteinDegraders #ClinicalTrials #OncologyInnovation #PrecisionMedicine #healthcareevolution

Peptides are emerging as a promising tool in our integrative oncology arsenal. These short chains of amino acids can play diverse roles in cancer treatment, from enhancing drug delivery to directly targeting cancer cells. A groundbreaking study published in Nature Reviews Cancer (2020) by Marqus et al. highlighted several key applications of peptides in oncology: 1. Targeted Drug Delivery: Peptides can act as "smart" carriers, delivering chemotherapy drugs directly to cancer cells, potentially reducing side effects and improving efficacy. 2. Immunotherapy Enhancement: Certain peptides can stimulate the immune system to better recognize and attack cancer cells. 3. Anti-angiogenic Effects: Some peptides can inhibit the formation of new blood vessels that feed tumors, potentially slowing cancer growth. 4. Direct Anti-tumor Activity: Specific peptides have shown the ability to induce cancer cell death. One particularly promising peptide, LTX-315, has shown remarkable results in early clinical trials. A study in the Journal of ImmunoTherapy of Cancer (2019) reported that LTX-315 increased immune cell infiltration in tumors and enhanced the effects of immunotherapy. As with any emerging treatment, it's crucial to note that many peptide therapies are still in research phases. However, the potential for personalized, targeted treatments with fewer side effects is exciting. Interested in learning more about how peptides might fit into your cancer care plan? Let's discuss the latest research and potential applications in your treatment. Book a consultation with me at SpeakWithDrSamm.com. Subscribe to my newsletter 📨 at naturopathicnuggets.com for exclusive content, and exciting updates delivered directly to your inbox. 📢 Join the conversation and stay informed! #DrSamm #DrSammND #PeptideTherapy #CancerResearch #IntegrativeOncology #PersonalizedMedicine

OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study - HIT Consultant #Partnership: OncoHost and Dana-Farber Collaborate on RCC Biomarker Study OncoHost, a precision oncology company, has partnered with Dana-Farber Cancer Institute to conduct a biomarker study focused on renal cell carcinoma (RCC). #StudyObjective: Identifying Biomarkers for RCC Treatment The objective of the study is to identify biomarkers that can help in the treatment of RCC, a type of kidney cancer. #PrecisionMedicine: Personalized Treatment Approaches for RCC Patients Through this collaboration, OncoHost and Dana-Farber aim to develop personalized treatment approaches for RCC patients based on biomarker analysis. #ClinicalTrials: Testing Biomarker-Based Treatments The study will involve ai.mediformatica.com #cancer #research #this #biomarkers #patients #study #outcomes #better #collaboration #danafarbercancerinstitute #medicine #patientoutcomes #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4e33wUt)

"New Breakthrough! Chinese Medical Team's Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer! " On May 25, 2024, the Journal of Clinical Oncology (JCO) published groundbreaking research by Professor Lin Shen's team from Peking University Cancer Hospital on the application of CLDN18.2 CAR-T cell therapy for refractory metastatic pancreatic cancer, achieving impressive outcomes! This study summarized the results of two phase I/Ib prospective clinical trials, involving a total of 24 advanced pancreatic cancer patients. Observations post-treatment revealed partial tumor shrinkage and significant reductions in CA19-9 levels in some patients, indicating a positive response. The research also demonstrated that CLDN18.2 CAR-T therapy not only showed significant efficacy in second- and third-line treatments but also exhibited promising potential in extending patient survival. Assessment of treatment safety showed that the safety profile of CT041 cell therapy in this study was similar to previous findings, with no predefined dose-limiting toxicities observed. Treatment-related adverse events were mainly manageable, with cytokine release syndrome (CRS) and gastrointestinal adverse events typically mild and alleviated through proactive clinical management. The results of this study demonstrate the potential and prospects of CLDN18.2 CAR-T cell therapy in CLDN18.2-positive metastatic pancreatic cancer patients. Significant reductions in CA19-9 levels, a disease control rate of 70.8%, and a significant extension of overall survival were observed, with treatment safety effectively controlled. The publication of these research findings brings new hope for pancreatic cancer patients and provides important references for further research and clinical application of #CLDN18.2 CAR-T cell therapy. We look forward to this breakthrough bringing gospel to more patients! To assess whether the condition is suitable for #CART or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation! WhatsApp: +8613717959070 Email: doctor.huang@globecancer.com  #PancreaticCancer #CARTTherapy #MedicalBreakthrough #Pancreatic

Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. The test, ImPrintTN, shows promising results improving the selection of immunotherapy drugs and minimizing the risk of adverse effects. This means that patients who are unlikely to respond to these drugs can avoid the adverse side effects associated with them and can be treated with other therapies. Prof. Laura van 't Veer presented the findings from the I-Spy2 phase 2 clinical trial at the 14th European Breast Cancer Conference suggesting a need to reconsider the current standard of care. This groundbreaking advancement marks a significant step towards tailored treatment strategies in breast cancer care. You can read more about Prof. Laura van ’t Veer’s presentation and results of the clinical trial below. . . .  #NonProfit #HealthEquity #breastcancerawareness #breastcancercure #cancer #earlyscreening #clinicaltrials #cancertrials #breastcancertrials #breastcancerresearch #breastcancertreatment #breastcancersupport #clinicalresearch #cancerresearch #Hopeforbreastcancer #Fightagainstbreastcancer #Breastcancertherapy #breastcancermedicine #breastcancerpatients #womenshealth #breastcancercommunity #diseaseresearch #datacollection #BCSM #cancerdata #researchdata #findacure

🔬 Exciting research alert! ATAD2, a key protein in tumor progression, shows promising potential as a biomarker for cancer diagnosis and prognosis. Check out the comprehensive study analyzing its expression, diagnostic value, and role in immune interaction across various cancer types. Explore the study findings on ATAD2's overexpression in cancers, its impact on prognosis, and its correlation with immune checkpoints. The research sheds light on ATAD2's oncogenic functions in papillary thyroid carcinoma, highlighting its potential as a therapeutic target for enhancing anti-tumor immune therapies. Read the full study here: https://lnkd.in/eiiYcuJy #CancerResearch #Biomarkers #Immunotherapy #TumorProgression 🧪🩺🔍

2024 has been a year full of articles so far! 📃 Now you could read our group's latest article showcasing that "precision oncology is not a static but dynamic and reactive process" and "remarkable responses could be achieved after initial treatment failure", which is uncommon with conventional treatment strategies 👏 #PrecisionOncology #NewArticle